Trial Profile
A prospective study investigating the effect of sunitinib and association of clinical response with peripheral blood immune cells and serum inflammatory markers in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- 09 Dec 2015 New trial record